Novo remains the largest shareholder in the endocrine disorder drug developer, which went public in an upsized offering.
Spruce Biosciences, a US-based developer of treatments for endocrine disorders, has floated in a $90m initial public offering representing an exit for pharmaceutical firm Novo.
The company increased the number of shares in the offering from 5 million to 6 million and priced them at $15.00 each, in the middle of the $14 to $16 range it set last week, valuing it at $334m. It listed on the Nasdaq Global Select Market and closed trading at $17.00 on Friday.
…
